By Marc Darrow, MD, JD

Can Wharton’s jelly or an umbilical cord product help pain traveling from the back into the leg? Emerging research makes this a reasonable question. Answering it requires identifying the pain source and separating promising investigation from an established treatment.

Patients sometimes come to us with pain that travels from the lower back or buttock into the leg. Some have been told they have sciatica. Others have already undergone a spinal operation and are trying to understand why they still hurt.

The first question is what is generating the pain now. A diagnosis made before surgery, or a finding on an MRI, does not automatically explain the current symptoms. At the same time, persistent leg pain should not automatically be attributed to a ligament or muscle. Nerve compression, joint pain, and soft-tissue pain can overlap.

Understanding Sciatica and Its Symptoms

Sciatica, radicular pain, and referred pain are different descriptions

Sciatica commonly describes pain extending down the leg in a pattern associated with irritation of a lumbar nerve root or the sciatic nerve. A disc herniation or spinal narrowing can contribute. Radiculopathy refers to nerve-root dysfunction, which may produce weakness, sensory changes, or altered reflexes. Radicular pain can occur without all of those findings.

Pain can also travel from a musculoskeletal structure without a nerve root being the primary source. This is referred pain. A 2025 review describes conditions that can mimic or coexist with radiculopathy, including hip arthritis, greater trochanteric pain, myofascial pain, and other disorders. (1)

Why examination matters even when you have an MRI

The examination helps connect the symptoms with the anatomy. It considers sensation, strength, reflexes, walking, spinal and hip movement, and the activities that bring on pain. That information can support—or challenge—the explanation suggested by a scan.

Degenerative findings are common in people without back pain. A systematic review of 3,110 asymptomatic individuals found that disc degeneration and bulging became increasingly common with age. These findings need clinical interpretation. (2)

This does not make MRI irrelevant. A scan can identify important compression or another structural problem. The useful question is whether its location and severity fit the symptoms and examination.

Electromyography and nerve-conduction testing may help distinguish nerve-root dysfunction from peripheral nerve disorders when the diagnosis is uncertain. They are not mandatory for every patient with sciatica, and a normal study does not exclude every cause of radicular pain.

What changes after back surgery?

Persistent pain after surgery is sometimes called failed back surgery syndrome or post-laminectomy syndrome. The term persistent spinal pain syndrome type 2 is increasingly used because it describes the problem without assuming that every painful outcome reflects a failed procedure.

A 2024 review identifies several possible sources: recurrent or residual structural disease, incomplete fusion, adjacent-level problems, altered mechanics, muscle wasting, scar-related processes, and persistent nerve pain. In some patients, the explanation remains uncertain. (3)

The distinction between unchanged pain, new pain, and pain that returned after an initial improvement matters. It can help determine which possibilities deserve investigation. None of those patterns, by itself, proves a particular cause.

Persistent postoperative back pain and radiating leg pain may overlap, but they require a fresh assessment of the current symptoms and neurologic findings.

The SI joint, muscles, and neighboring spinal levels

After fusion, assessment may need to extend beyond the operated level. A 2024 systematic review of twelve observational studies involving 3,570 patients estimated new-onset sacroiliac joint pain after spinal surgery at approximately 9.4%. Multilevel surgery and fusion to the sacrum were among associated factors. The findings do not establish the cause of an individual’s pain. (4)

Symptoms near the SI joint need careful differentiation from lumbar nerve-root pain.

Muscles and fascia also deserve attention after surgery. Changes in muscle health may be relevant without proving that muscle damage explains every case or that an injection reverses muscle atrophy.

Likewise, imaging degeneration next to a fusion is different from symptomatic adjacent segment disease. A neighboring level needs to fit the clinical problem before it is selected for treatment.

Nonsurgical care still has a role

Treatment after surgery may include rehabilitation, medicines selected for the pain mechanism, and specific interventions when appropriate. Persistent pain can also affect sleep, confidence in movement, and daily function. Addressing these consequences does not mean that the pain is imaginary.

A 2024 review emphasizes identifying the cause, setting realistic goals, and using a multidisciplinary approach when needed. It includes physical therapy, medication, psychological support, and interventions rather than presenting repeat surgery as the default response. (5)

For someone considering PRP or marrow treatment, the relevant issue is whether there is a suitable target and a reasonable evidence-based expectation. Having exhausted one treatment does not establish that the next injection will work.

Can Wharton’s jelly be a realistic option for sciatica?

Wharton’s jelly deserves a serious research discussion, particularly when a person has persistent pain involving spinal connective tissues. The realistic possibility is narrower than a promise to “repair the sciatic nerve.” At present, donor cord-tissue products remain investigational for these uses, and strong controlled evidence for treating lumbar radiculopathy with non-expanded Wharton’s jelly is lacking.

In my assessment, the first distinction is between pain from an irritated nerve root and pain referred from nearby structures. A patient may have both. A treatment directed at paraspinal muscle or an attachment site could conceivably help a confirmed soft-tissue component without treating the nerve compression responsible for leg weakness. That distinction determines how the research should be interpreted.

What Wharton’s jelly contains—and what that does not prove

Wharton’s jelly is the connective tissue surrounding the umbilical cord’s blood vessels. A laboratory characterization of one processed preparation detected hyaluronic acid, growth factors, cytokines, and membrane-enclosed particles. These findings help explain scientific interest in the tissue’s matrix and signaling environment. They do not establish a therapeutic dose for sciatica or show that an injection repairs a disc or nerve. Commercial affiliations were disclosed in this study. (6)

Processing changes what remains in the finished product. A Wharton’s jelly allograft is not automatically a preparation of viable stem cells, and findings from cells expanded in a laboratory cannot be used as proof for a non-expanded tissue product.

2026 spinal soft-tissue study: an encouraging but preliminary signal

An observational study examined 117 patients receiving one to three umbilical cord tissue allograft applications for paraspinal muscle and attachment-site problems in the thoracic or lumbar region. Patient-reported pain and function measures improved, and no adverse events were reported. However, there was no control group, treatment protocols varied, and outcomes relied on patient reports. Several authors were affiliated with the manufacturer.

This supports further investigation of spinal soft-tissue pain. It does not demonstrate reversal of muscle degeneration, disc regeneration, or relief of confirmed nerve-root compression. It was not a controlled trial establishing Wharton’s jelly as a treatment for sciatica. (7)

A registered lumbar-pain pilot is not yet an answer

ClinicalTrials.gov lists NCT06361485, an open-label, uncontrolled pilot studying Wharton’s jelly allograft injections for chronic lumbar pain, with estimated enrollment of 100. At this review, no results were posted. Its record still listed recruiting, but the last posted update was April 11, 2024, so current recruitment cannot be assumed. A planned study demonstrates interest in the question; it does not establish benefit or prove effectiveness for radiculopathy. (8)

Umbilical cord tissue, cord blood, and exosomes are different products

Product What matters for this discussion
Wharton’s jelly / cord-tissue allograft Processed donor connective tissue. Early spinal soft-tissue observations do not establish treatment of compressed nerve roots.
Umbilical cord blood preparation A blood-derived product, distinct from the cord’s matrix. Contents depend on processing; cord-tissue results cannot establish its effectiveness for sciatica.
Culture-expanded cord-derived cells Cells multiplied in a laboratory. They are not interchangeable with the non-expanded products discussed here.
Cord-derived exosome preparation Separately produced extracellular vesicles. Its clinical findings must be assessed independently of tissue allografts and cord blood.

Research on umbilical cord blood transplantation for spinal cord injury concerns a different disease, product, and procedure. It does not establish treatment for a lumbar disc herniation or postoperative sciatica. Donor origin and the label “stem cell” alone cannot tell a patient whether a product has an appropriate composition, dose, or evidence for the intended target.

New exosome research: relevant to discuss, too early to recommend routinely

A 2026 uncontrolled study in Laos enrolled 76 people with cervical or lumbar disc herniation who received an epidural cord-derived exosome preparation. The authors reported pain improvement, but only 42 were assessed at two years. There was no placebo group, follow-up relied on telephone assessments with a customized outcome scale, and no follow-up MRI established structural repair. The source cells were culture-expanded to manufacture the vesicles; this was not an injection of non-expanded Wharton’s jelly or cord blood.

The report is an early clinical observation, not evidence of equivalent benefit for commercial cord products or a basis for promising nerve regeneration. (9)

What would make consideration of a donor product realistic?

A realistic discussion begins with a defined pain source, stable neurologic findings, and a specific product and injection target that match the research question. It includes the uncertainty of benefit, established treatment alternatives, and appropriate regulatory oversight. It cannot begin with the assumption that a donor product is the next treatment simply because physical therapy or a steroid injection did not provide lasting relief.

Wharton’s jelly, cord-blood products, and exosomes have not been FDA-approved to treat sciatica, disc disease, or other orthopedic conditions. FDA registration and a ClinicalTrials.gov listing do not establish approval or lawful marketing. FDA states that these unapproved regenerative products require appropriate investigational oversight. Risks include infection, inflammatory or immune reactions, and failure to improve; injection around spinal nerves adds route-specific concerns. (10)

For patients interested in these approaches, a properly authorized clinical investigation is the most defensible setting for testing their potential. The research is developing, but it does not currently support presenting Wharton’s jelly or umbilical cord blood as a proven routine alternative to decompression when meaningful nerve compression is present.

What does research show about PRP for true lumbar radicular pain?

PRP is prepared from the patient’s blood and concentrates platelets. It is not a stem cell treatment. Its effects depend on the preparation, injection route, and condition being studied.

A 2025 meta-analysis of five randomized trials involving 310 patients compared epidural PRP with epidural steroid injections for lumbar disc disease with radiculopathy. Average pain and disability outcomes were comparable, with substantial variation between studies. (11)

A separate 2026 meta-analysis of three trials involving 132 patients found that steroids performed better for pain at one month, while PRP performed better for pain and disability at six months. This smaller analysis used a different selection of trials; it should not be interpreted as an independent population added to the earlier review. (12)

An October 2026 randomized trial reported outcomes for 107 patients with a single-level herniated disc and symptoms persisting despite six weeks of conservative treatment. Steroid injections produced better early outcomes, while PRP produced better pain and disability outcomes at six and twelve weeks. Follow-up was short, and the trial did not establish long-term nerve repair or effectiveness for postoperative patients. (13)

Together, these studies provide a clinical signal worth investigating. They do not establish PRP as a universal replacement for steroid injections or surgery. Nor does symptom improvement show that a herniation disappeared or that mechanical compression was removed.

Bone marrow treatment: the target changes the evidence

Bone marrow aspirate concentrate contains a mixture of cells and other components. Its stromal-cell population is different from a purified, culture-expanded cell product. This article considers non-expanded preparations.

In our 2018 four-patient series, marrow concentrate was injected into lumbar-region muscle, fascia, and ligament attachments. Patients reported improvement at one year. These observations support further investigation, but the study had no control group and could not establish tissue regeneration or effectiveness for nerve compression. (14)

In contrast, a 2025 double-blind trial tested marrow concentrate injected inside a disc in 63 patients with presumed discogenic back pain. It found no statistically significant advantage over a sham procedure in the primary pain-relief outcome. Limited characterization of the preparation was among the study’s limitations. (15)

Neither study answers every spine-treatment question. An injection into a disc, an epidural injection near a nerve root, and an injection into a soft-tissue attachment are different procedures. Their outcomes should not be grouped together as proof that “stem cells work for sciatica.”

Evidence for knee arthritis, donor cord products, or Wharton’s jelly also cannot establish effectiveness for postoperative lumbar nerve pain. The actual preparation and target need to match the research.

When surgery remains appropriate

Some patients improve with nonsurgical care; others have a structural problem for which surgery is appropriate. A 2023 systematic review found that discectomy could provide faster leg-pain relief for patients with a surgical indication, although benefits over nonsurgical treatment diminished over time and evidence certainty was low. (16)

Progressive weakness, a new foot drop, saddle numbness, or changes in bladder or bowel function require prompt assessment. A regenerative-treatment discussion should never delay evaluation of a potentially serious neurologic problem.

For elective repeat surgery, the key question is whether the proposed procedure addresses a clearly identified cause that fits the symptoms. Avoiding unnecessary surgery and recognizing necessary surgery are both part of good decision-making.

What matters more than age or where treatment is offered?

Being over 50 does not determine the pain source or automatically rule out nonsurgical options. Medical history, neurologic status, structural disease, and the person’s goals matter more than an age cutoff.

Likewise, travel abroad is not evidence that a product or procedure is more effective. The evidence, processing, oversight, and follow-up arrangements matter. FDA guidance states that regenerative therapies have not been approved for orthopedic conditions and warns about unapproved products marketed for these uses. (10)

The central question remains: what is producing the current pain, and what treatment has credible evidence for that problem? A better explanation of the symptoms makes the next decision more useful than another label on a scan.

Related reading

References

1 Bateman EA, Fortin CD, Guo M. Musculoskeletal mimics of lumbosacral radiculopathy. Muscle Nerve. 2025;71(5):816-832. doi:10.1002/mus.28106.

2 Brinjikji W, Luetmer PH, Comstock B, Bresnahan BW, Chen LE, Deyo RA, Halabi S, Turner JA, Avins AL, James K, Wald JT, Kallmes DF, Jarvik JG. Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. AJNR Am J Neuroradiol. 2015;36(4):811-816. doi:10.3174/ajnr.a4173.

3 van de Minkelis J, Peene L, Cohen SP, Staats P, Al-Kaisy A, Van Boxem K, Kallewaard JW, Van Zundert J. Persistent spinal pain syndrome type 2. Pain Pract. 2024;24(7):919-936. doi:10.1111/papr.13379.

4 Xu C, Lin X, Zhou Y, Zhuo H, Yang L, Chai X, Huang Y. Incidence and risk factors of new-onset sacroiliac joint pain after spinal surgery: a systematic review and meta-analysis. PeerJ. 2024;12:e18083. doi:10.7717/peerj.18083.

5 Yeo J. Failed back surgery syndrome-terminology, etiology, prevention, evaluation, and management: a narrative review. J Yeungnam Med Sci. 2024;41(3):166-178. doi:10.12701/jyms.2024.00339.

6 Gupta A, El-Amin SF III, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cord-derived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020;15:49. doi:10.1186/s13018-020-1553-7.

7 Tamea C, Buchalter J, Capra J, Gilliland T, Lambert N, Lee A, Barrett T. An Observational Study of Human Umbilical Cord Tissue Allografts for Paraspinal Muscle and Entheses Defects in the Thoracic and Lumbar Regions. Biomedicines. 2026;14(5):1030. doi:10.3390/biomedicines14051030.

8 ClinicalTrials.gov. Safety and Feasibility of Umbilical Cord Wharton’s Jelly Allograft Injections for Lumbar Pain. NCT06361485. Last posted update April 11, 2024. Registry accessed November 17, 2026.

9 Nguyen PC, Vu NB. Epidural Injection of Umbilical Cord-Derived Mesenchymal Stem Cell Exosomes for Chronic Spinal Pain: A Preliminary Clinical Evaluation. Biomed Res Ther. 2026;13(7):8844–8852. doi:10.15419/bmrat.v13i7.1090.

10 U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. FDA consumer guidance. Accessed November 17, 2026.

11 Muthu S, Viswanathan VK, Gangadaran P. Is platelet-rich plasma better than steroids as epidural drug of choice in lumbar disc disease with radiculopathy? Meta-analysis of randomized controlled trials. Exp Biol Med (Maywood). 2025;250:10390. doi:10.3389/ebm.2025.10390.

12 Ermawan R, Corrigan H, Fachreza MS, Mercy G, Angeline A, Jiwandono BS, Yudistiro I, Abdulhamid M. Epidural Platelet-Rich Plasma Long-Term Outcome Is Better Than Steroid for Prolapsed Lumbar Intervertebral Discs: A Meta-Analysis of Randomized Controlled Trials. Spine Surg Relat Res. 2026;10(1):36-42. doi:10.22603/ssrr.2025-0007.

13 Sonkar T, Yadav V, Singh S. A randomized controlled trial comparing transforaminal injections of Platelet-rich plasma versus steroid for lumbar herniated disc. J Clin Orthop Trauma. 2026;81:103546. doi:10.1016/j.jcot.2026.103546.

14 Darrow M, Shaw B. Treatment of Lower Back Pain with Bone Marrow Concentrate. Biomed J Sci Tech Res. 2018;7(2). Article 001461. doi:10.26717/BJSTR.2018.07.001461.

15 Levi D, Tyszko S, Horn S, Pham N, Levin J. Bone marrow concentrate intradiscal injection for chronic discogenic low back pain: A double-blind randomized sham-controlled trial. Interv Pain Med. 2025;4(3):100611. doi:10.1016/j.inpm.2025.100611.

16 Liu C, Ferreira GE, Abdel Shaheed C, Chen Q, Harris IA, Bailey CS, Peul WC, Koes B, Lin CC. Surgical versus non-surgical treatment for sciatica: systematic review and meta-analysis of randomised controlled trials. BMJ. 2023;381:e070730. doi:10.1136/bmj-2022-070730.